PA5-36200
antibody from Invitrogen Antibodies
Targeting: MED1
CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-36200 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TRAP220 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody detects endogenous protein at a molecular weight of 170 kDa.
- Concentration
- 1 mg/mL
Submitted references miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy.
Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM
Cancers 2018 Aug 25;10(9)
Cancers 2018 Aug 25;10(9)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of TRAP220 in Lane 1: A549 whole cell lysate (40 µg), Lane 2: HEK293T whole cell lysate (40 µg), Lane 3: PC12 whole cell lysate (40 µg), Lane 4: CT26 whole cell lysate (40 µg). Samples were incubated with TRAP220 polyclonal antibody (Product # PA5-36200) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of TRAP220/MED1 using TRAP220/MED1 polyclonal antibody (Product # PA5-36200) at a dilution of 1:500. Lane 1: HEK293T whole cell lysate, Lane 2: Raw264.7 whole cell lysate, Lane 3: PC12 whole cell lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of TRAP220/MED1 in paraffin-embedded human breast carcinoma using TRAP220/MED1 polyclonal antibody (Product # PA5-36200) at a dilution of 1:100.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of TRAP220/MED1 in paraffin-embedded human breast carcinoma using TRAP220/MED1 polyclonal antibody (Product # PA5-36200) at a dilution of 1:100.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 miR-205-NPs inhibits EMT signaling and sensitizes Dtxl treatment in PrCa cells. ( A ) miR-205-NPs treatment suppresses the migratory ability of C4-2 and PC-3 cells in presence/absence of the drug through Boyden chamber study. Images were captured at 20x magnification. Transwell assay with matrigel was performed to detect invasion activity of PrCa cells transfected with miR-205. Docetaxel treatments at 5 nM concentration. Scale bar: 200 um. ( B ) Protein profiling studies of Control, miR-205 transfected and miR-205-NPs treated PrCa cells for 24 h for EMT signaling. Note: miR-205-L or miR-205-Lipo represents same and indicates to miR-205 transfected with lipofectamine.